ResMed Stock Slides 8.6% Over 8 Straight Down Days

A persistent slide in ResMed's stock has drawn attention, but the company's financial metrics tell a different story.

ResMed (RMD) stock has now moved lower for 8 consecutive trading days, a slide that has cut its price by a cumulative 8.6%. The streak has erased about $3.0 billion from the company's market value, which now stands at about $32 billion.

For anyone holding the shares, this persistent selling pressure marks a significant turn after a period of recent strength.

The Streak Next To The S&P 500

Here is how RMD stock stacks up against the S&P 500 over the streak and the periods around it:

The stock's price move appears disconnected from its fundamentals.

Available news sources and regulatory filings show no specific company catalyst or headline driving the 8-day slide. Looking at the business profile, ResMed's revenue over the last twelve months grew 9.9%-down slightly from its 3-year average annual growth rate of 10.2%, though still above the S&P 500 median of 8.3%. Its operating margin stands at 33.8%, well above the index median of 18.6%.

Despite this, the stock trades at a price-to-earnings multiple of 20.9, below both the S&P 500 median of 22.6 and the 25.0 median for Health Care stocks. The selling is also largely specific to the stock, given that the S&P 500 fell just 1.6% over the same 8 trading days. Across the broader index, 6 other stocks are currently on losing streaks of 8 days or more.

A streak is information, not an instruction.

A long run of selling or buying is a signal about momentum and where other investors are focused. It is not, by itself, a reason to act. The disciplined response is to check the business against the price. The numbers here show a profitable, growing company with a free cash flow yield of 5.1% trading at a below-median multiple, providing a starting point for that assessment.

A slide like this always poses the same follow-up: which marked-down stocks are actually worth buying? Our Buy the Dip screen runs that test every day, flagging beaten-down names whose fundamentals still hold up.

Those watching the group rather than this one name have another route: our ETF Scorecard shows how the healthcare funds stack up. Even so, rotating into healthcare ETFs is still a concentrated bet on a single sector, which is precisely the gap the multi-theme portfolio below addresses.

Falling prices test conviction. Rules do not flinch

A losing streak forces a choice on every holder: sell into weakness, average down, or freeze. All three are emotional answers to what should be an analytical question, and emotions priced at market open are expensive.

The Trefis High Quality (HQ) Portfolio takes the emotion out: about 30 quality businesses screened for the fundamentals that survive bad stretches, held and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices - the S&P 500, S&P Mid-cap, and Russell 2000. Let the rules do the heavy lifting for you.